المؤلفون: Jatoi, Aminah, Ou, Fang-Shu, Ahn, Daniel H., Zemla, Tyler J., Le-Rademacher, Jennifer G., Boland, Patrick, Ciombor, Kristen K., Jacobs, Nisha L., Pasche, Boris, Cleary, James M., McCune, Jeannine S., Pedersen, Katrina S., Barzi, Afsaneh, Chiorean, E. Gabriela, Heying, Erica N., Lenz, Heinz-Josef, Sloan, Jeff A., Grothey, Axel, Lacouture, Mario E., Bekaii-Saab, Tanios

المصدر: The Oncologist ; volume 26, issue 7, page 610-618 ; ISSN 1083-7159 1549-490X

الوصف: Background Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. Materials and Methods The Regorafenib Dose Optimization Study (ReDOS), a four-arm, previously published trial with a 1:1:1:1 randomization scheme, was analyzed in a manner in keeping with the original protocol to assess whether clobetasol 0.05% cream (a corticosteroid) applied to the palms and soles twice per day for 8 weeks was more effective when prescribed preemptively (before the development of HFSR) versus reactively (after the development of HFSR). Patients were assessed during the first two cycles of regorafenib. Results Sixty-one patients received preemptive clobetasol, and 55 received reactive clobetasol. Groups were balanced on demographics. Over the first two cycles, no evidence of HFSR occurred in 30% with preemptive clobetasol versus 13% with reactive clobetasol (p = .03). During the first cycle, 54% and 45% of patients had no HFSR with preemptive and reactive clobetasol, respectively (p = .35). During the second cycle, 33% and 15% had no HFSR with preemptive and reactive clobetasol, respectively (p = .02). During the second cycle, rates of grade 1, 2, and 3 HFSR were 30%, 8%, and 3%, respectively, with preemptive clobetasol and 43%, 18%, and 7%, respectively, with reactive clobetasol (p = .12). Patient-reported outcomes showed HFSR compromised nearly all activities of daily living with worse quality of life in patients who received reactive versus preemptive clobetasol. No clobetasol-induced adverse events were reported. Conclusion Preemptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort. Implications for Practice Regorafenib causes hand-foot skin reactions. Preemptive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse ...

الإتاحة: https://doi.org/10.1002/onco.13730Test
https://academic.oup.com/oncolo/article-pdf/26/7/610/42367278/oncolo_26_7_610.pdfTest

المؤلفون: Smith, Jonathan H., Jacobs, Nisha L., Ficalora, Robert D.

المصدر: Mayo Clinic Proceedings ; volume 85, issue 3, page 280-283 ; ISSN 0025-6196

مصطلحات موضوعية: General Medicine

الإتاحة: https://doi.org/10.4065/mcp.2009.0173Test
https://api.elsevier.com/content/article/PII:S002561961160414X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S002561961160414X?httpAccept=text/plainTest

المؤلفون: Bekaii-Saab, Tanios S, Ou, Fang-Shu, Ahn, Daniel H, Boland, Patrick M, Ciombor, Kristen K, Heying, Erica N, Dockter, Travis J, Jacobs, Nisha L, Pasche, Boris C, Cleary, James M, Meyers, Jeffrey P, Desnoyers, Rodwige J, McCune, Jeannine S, Pedersen, Katrina, Barzi, Afsaneh, Chiorean, E Gabriela, Sloan, Jeffrey, Lacouture, Mario E, Lenz, Heinz-Josef, Grothey, Axel

المصدر: The Lancet Oncology ; volume 20, issue 8, page 1070-1082 ; ISSN 1470-2045

مصطلحات موضوعية: Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(19)30272-4
https://api.elsevier.com/content/article/PII:S1470204519302724?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1470204519302724?httpAccept=text/plainTest

المؤلفون: Jacobs, Nisha L., Holtan, Shernan G., Porrata, Luis F., Markovic, Svetomir N., Tefferi, Ayalew, Steensma, David P.

المصدر: American Journal of Hematology ; volume 85, issue 3, page 160-163 ; ISSN 0361-8609 1096-8652

الوصف: The prognostic significance of the peripheral blood absolute lymphocyte count (ALC) has been carefully examined in lymphoid malignancies, but the importance of the baseline ALC in chronic myeloid neoplasms is less clear. In a recent analysis of myelodysplastic syndromes (MDS) associated with deletion of chromosome 5q, we observed that an ALC < 1.2× 10 9 cells/L at diagnosis is independently associated with poorer survival. Clinicopathological data from 503 patients with non‐del(5q) MDS evaluated at Mayo Clinic between 1996 and 2007 were reviewed to determine the prognostic impact of ALC at diagnosis in non‐del(5q) MDS. Patients with MDS and an ALC at diagnosis ≥1.2× 10 9 ( N = 248) experienced a superior overall survival (OS) compared with patients with an ALC < 1.2× 10 9 /L ( N = 255, median OS of 26.6 months versus 18.5 months, P < 0.001, respectively). ALC at diagnosis was an independent predictor for OS when compared with the International Prognostic Scoring System and the WHO‐based Prognostic Scoring System. This study suggests that ALC at diagnosis is a prognostic factor for OS in MDS, and argues in favor of further studies to assess the role of host immunity in MDS clinical outcomes. Am. J. Hematol. 2010. © 2009 Wiley‐Liss, Inc.

الإتاحة: https://doi.org/10.1002/ajh.21618Test

المؤلفون: Jacobs, Nisha L., Que, Florencia G., Miller, Robert C., Vege, Santhi Swaroop, Farnell, Michael B., Jatoi, Aminah

المصدر: Journal of Gastrointestinal Cancer ; volume 40, issue 1-2, page 46-50 ; ISSN 1941-6628 1941-6636

مصطلحات موضوعية: Gastroenterology, Oncology

الإتاحة: https://doi.org/10.1007/s12029-009-9082-yTest

المؤلفون: Jacobs, Nisha L, Holtan, Shernan G, Porrata, Luis F, Markovic, Svetomir N, Tefferi, Ayalew, Steensma, David P.

المصدر: Blood; November 2008, Vol. 112 Issue: 11 p3633-3633, 1p

مستخلص: Background:The prognostic significance of lymphocyte counts and immune status has been carefully examined in lymphoid malignancies, but the importance of the lymphocyte count in chronic myeloid neoplasms is less clear. In a recent analysis of MDS cases associated with deletion of chromosome 5q (Holtan SG et al AmJHem2008 Epub 12Jun), we observed that an ALC >1.2 × 109cells/L at diagnosis is independently associated with improved survival. The prognostic value of ALC in MDS not associated with del(5q) is unknown.